Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- US FDA Accepts Relugolix for Review in Advanced Prostate Cancer
June 24, 2020
- Ayumi Chief Says Contender Debut Will Add Vigor to Enbrel Biosimilar Space, Sees Govt Fee Incentive as Booster
June 23, 2020
- Takeda to Book One-Time Profit Gains after SHP647 Divestment Obligation Cleared
June 23, 2020
- Celgene’s CAR-T Therapy Filed in Japan for B-Cell Lymphoma: BMS
June 23, 2020
- Shionogi Licenses Rapid COVID-19 Diagnostic Methods Developed by 3 Universities
June 23, 2020
- Latuda Challenged Again over Use Patent Validity in US: Sumitomo Dainippon
June 23, 2020
- Sawai Snaps Up Rights for ALS Drug Candidate from Tokai Univ. Spin-Off, Its 1st Orphan Development
June 23, 2020
- Lilly Japan Chief Sees Continued Diabetes Investment as Key to Remaining in Top 10
June 22, 2020
- Shionogi Preparing Commercial Production of COVID-19 Vaccine Simultaneously with Development
June 22, 2020
- Sawai to Halt Erythromycin Shipment by July End due to Deviations from Specifications
June 22, 2020
- Oncolys Strikes Deal with Kagoshima Univ. to Develop COVID-19 Therapy
June 22, 2020
- Urovant, Sunovion Ink Distribution Pact for OAB Med Vibegron; Both Sumitomo Dainippon Units
June 22, 2020
- Pfizer Launches Celecox Authorized Generic, Its 1st AG
June 22, 2020
- Crysvita Approved for Tumor-Induced Osteomalacia in US: Kyowa Kirin/Ultragenyx
June 22, 2020
- Keytruda Logs 64% Growth, Tops FY2019 Drug Ranking: Jiho Tally
June 19, 2020
- 5 Authorized Generics Hit Japan Market on June 19
June 19, 2020
- Ono President Confident of Validity of Company’s Argument on Opdivo Royalties
June 19, 2020
- AZ Recalls Omepral Injection in Japan due to Flaws in Environmental Monitoring Data
June 19, 2020
- NanoCarrier’s NC-6004 Hits Goal in Keytruda Combo for Head and Neck Cancer
June 19, 2020
- Lilly’s Ultra-Fast Acting Insulin Lyumjev Now Available in Japan
June 18, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…